Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd (KIMS) has announced the closure of its trading window to facilitate the consideration of its unaudited financial results for the second quarter and half-year ending September 30, 2026. The window will be shut from October 1, 2026, and will reopen 48 hours after the announcement of the results. During this period, directors, designated employees, insiders, and their immediate relatives are prohibited from trading in the company's securities. The specific date of the board meeting to approve these results will be communicated separately.

Catalyst Trusteeship Limited, acting as Debenture Trustee, has disclosed the pledge of 2,80,08,979 equity shares of Krishna Institute of Medical Sciences Limited (KIMS). This represents 6.66% of the total share capital. The pledge was made by Bhaskara Rao Bollineni and Bollineni Seenaiah Naidu in favor of Catalyst Trusteeship on behalf of debenture holders. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Krishna Institute of Medical Sciences Ltd (KIMS) has entered into an Operations and Management (O&M) Agreement with Sarvottam Health Care Private Limited (SHPL) in Kakinada, Andhra Pradesh. The agreement is for an initial term of 5 years, with an option for a further 5-year extension, granting KIMS exclusive rights to manage, operate, and control SHPL's hospital. KIMS will receive a revenue fee of 9% of the hospital's Net Revenue. This deal expands KIMS' presence in Andhra Pradesh and leverages SHPL's existing infrastructure, including a 183-bed hospital.

Krishna Institute of Medical Sciences Ltd (KIMS) has issued a clarification refuting a news report by Dealstreetasia.com alleging talks to acquire a stake in Renova Hospitals for $52 million. KIMS states that the report is false, baseless, and factually incorrect. The company has not entered into any agreement, MOU, or discussions regarding this alleged acquisition. KIMS assures compliance with SEBI regulations and will disclose material developments as required.

Krishna Institute of Medical Sciences Ltd (KIMS) has entered into an Operations and Management (O&M) Agreement and a Call Option Agreement with Aurevia Hospitals Private Limited (AHPL), formerly Golden Lan Solution Private Limited. The O&M agreement, for an initial term of 5 years with a possible 5-year extension, grants KIMS the exclusive right to manage, operate, and control the Arete Hospitals, which AHPL acquired. KIMS will provide medical services at Arete and is entitled to a revenue fee of 9% of the hospital's total Net Revenue. The Call Option Agreement gives KIMS the option, but not the obligation, to acquire AHPL's business under specified terms. This move expands KIMS' presence in Hyderabad, a region with significant growth potential.

Krishna Institute of Medical Sciences Ltd has approved the allotment of 77,02,182 warrants on a preferential basis to its promoters: Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. The company has received ₹1,499,999,944.50, representing 25% of the issue price, for these warrants. The remaining 75% will be payable upon exercise of the conversion rights. These warrants are convertible into equity shares within 18 months. The allotment is expected to increase the promoter and promoter group's shareholding from 32.50% to 33.71% upon full conversion.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has received in-principle approval from BSE and NSE for the preferential issue and allotment of 77,02,182 warrants, convertible into equity shares, to its promoters and promoter group. The issue price for conversion is not less than ₹779 per share. The exchanges have advised the company to strengthen internal controls and obtain undertakings from allottees regarding trading restrictions to ensure compliance with SEBI regulations. KIMS Hospitals must also comply with post-allotment listing formalities within twenty days.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26, along with a Reasonable Assurance Report from M/s. Brahmayya & Co. The report, which is part of the Integrated Annual Report, details the company's performance against the National Guidelines on Responsible Business Conduct (NGRBC) and SEBI's BRSR framework. It highlights KIMS's approach to ethical governance, sustainability in service delivery, employee well-being, stakeholder inclusiveness, human rights, environmental responsibility, and public policy advocacy. The BRSR emphasizes the integration of sustainability across operations to enhance resilience, improve healthcare outcomes, and create long-term value for all stakeholders.

Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) has submitted its 24th Integrated Annual Report for the Financial Year 2025-26. The report, sent electronically to members, details the company's expansion, operational highlights, and financial performance. KIMS Hospitals operates a network of 26 branches across five states, emphasizing clinical excellence and patient-centric care. The report includes financial statements, statutory reports, and management discussions, highlighting a revenue of ₹39,308 Mn and an EBITDA margin of 21.1% for FY26. The company's vision is to maximize reach and become the most preferred healthcare brand through affordable care and best clinical outcomes.

Krishna Institute of Medical Sciences Ltd has announced its 24th Annual General Meeting (AGM) will be held on August 27, 2026, at 4:00 PM IST. The meeting will be conducted virtually via Video Conferencing/Other Audio Visual Means (VC/OAVM). Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year ended March 31, 2026, the re-appointment of Ms. Dandamudi Anitha as a Director, ratification of remuneration for Cost Auditors M/s. Sagar & Associates for FY 2026-27, and approval for granting loans, guarantees, or securities up to ₹650 Cr to group entities under Section 185 of the Companies Act, 2013.